Clinical Trials Directory

Trials / Unknown

UnknownNCT04640363

Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Chinese PLA General Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Combined F index, A index,ATT index and spleen stiffness to predict tumor recurrence in different liver settings after thermal ablation of HCC.

Detailed description

Thermal ablation is one of the established method for HCC treatment. Postoperative recurrence of HCC is one of the major factors leading to poor prognosis of HCC patients. Most studies have shown that the risk factors of recurrence include tumor size, tumor number and intrahepatic spread, etc. Besides, the carcinogenic effects of inflammatory activity and fibrosis in liver background caused by chronic hepatitis also be related to the recurrence. In the study, combi-elastography imaging technology , not only the F index which is related to liver fibrosis stage can be obtained, but also the A index which is related to inflammation activity can be measured, this may provide a more valuable method for tumor recurrence of early prediction.

Conditions

Timeline

Start date
2020-12-01
Primary completion
2023-12-31
Completion
2024-05-31
First posted
2020-11-23
Last updated
2021-01-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04640363. Inclusion in this directory is not an endorsement.